These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25572009)

  • 1. Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
    Rogalińska M; Błoński JZ; Góralski P; Wawrzyniak E; Hartman M; Rogalska A; Robak P; Koceva-Chyła A; Piekarski H; Robak T; Kiliańska ZM
    Int J Oncol; 2015 Mar; 46(3):1259-67. PubMed ID: 25572009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
    Rogalinska M; Goralski P; Wozniak K; Bednarek JD; Blonski JZ; Robak T; Piekarski H; Hanausek M; Walaszek Z; Kilianska ZM
    Leuk Res; 2009 Feb; 33(2):308-14. PubMed ID: 18676014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
    Zolnierczyk JD; Błoński JZ; Robak T; Kiliańska ZM; Wesierska-Gadek J
    Ann N Y Acad Sci; 2009 Aug; 1171():124-31. PubMed ID: 19723046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
    Żołnierczyk JD; Borowiak A; Błoński JZ; Cebula-Obrzut B; Rogalińska M; Kotkowska A; Wawrzyniak E; Smolewski P; Robak T; Kiliańska ZM
    Pharmacol Rep; 2013; 65(2):460-75. PubMed ID: 23744431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
    J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
    Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
    Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
    Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
    Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
    Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purine analogs in the treatment of chronic lymphocytic leukemia.
    Pott C; Hiddemann W
    Leukemia; 1997 Apr; 11 Suppl 2():S25-8. PubMed ID: 9178834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases.
    Rogalińska M; Franiak-Pietryga I; Błoński JZ; Góralski P; Maciejewski H; Janus A; Robak P; Mirowski M; Piekarski H; Robak T; Kiliańska ZM
    Cancer Biol Ther; 2013 Jan; 14(1):6-12. PubMed ID: 23114648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
    Rogalińska M; Błoński JZ; Komina O; Góralski P; Zołnierczyk JD; Piekarski H; Robak T; Kiliańska ZM; Wesierska-Gadek J
    J Cell Biochem; 2010 Jan; 109(1):217-35. PubMed ID: 19911397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
    Morande PE; Zanetti SR; Borge M; Nannini P; Jancic C; Bezares RF; Bitsmans A; González M; Rodríguez AL; Galmarini CM; Gamberale R; Giordano M
    Invest New Drugs; 2012 Oct; 30(5):1830-40. PubMed ID: 21887502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
    Robak P; Linke A; Cebula B; Robak T; Smolewski P
    Leuk Lymphoma; 2006 Dec; 47(12):2625-34. PubMed ID: 17169808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
    Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells.
    Pellacani A; Tosi P; Zinzani PL; Ottaviani E; Albertini P; Magagnoli M; Tura S
    Leuk Lymphoma; 1999 Mar; 33(1-2):147-53. PubMed ID: 10194132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.